Cancer Research Donn Young Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hempen, P. M.
Right arrow Articles by Kern, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hempen, P. M.
Right arrow Articles by Kern, S. E.
[Cancer Research 63, 994-999, March 1, 2003]
© 2003 American Association for Cancer Research

Experimental Therapeutics

Evidence of Selection for Clones Having Genetic Inactivation of the Activin A Type II Receptor (ACVR2) Gene in Gastrointestinal Cancers1

Paula M. Hempen, Lin Zhang, Ravi K. Bansal, Christine A. Iacobuzio-Donahue, Kathleen M. Murphy, Anirban Maitra, Bert Vogelstein, Robert H. Whitehead, Sanford D. Markowitz, James K. V. Willson, Charles J. Yeo, Ralph H. Hruban and Scott E. Kern2

Departments of Oncology [P. M. H., L. Z., R. K. B., B. V., R. H. H., S. E. K.], Pathology [C. A. I-D., K. M. M., A. M., R. H. H., S. E. K.], and Surgery [C. J. Y.], The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232 [R. H. W.]; Ireland Cancer Center, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio 44106 [S. D. M., J. K. V. W.]; and Howard Hughes Medical Institutes, Chevy Chase, Maryland 20815 [B. V., S. D. M.]

The activin signaling pathway parallels the transforming growth factor (TGF)-ß pathway. Both use extracellular ligands and cell surface receptors that are structurally and functionally related, as well as the same intracellular mediators (SMADs 2–4) to transmit these signals. Members of both pathways have been characterized previously as tumor suppressor genes on the demonstration of inactivating mutations in human neoplasms, e.g., genetic inactivation of the activin type I receptor was reported recently in pancreatic cancer. Here, we present evidence of selection for mutations of the activin A type II receptor (ACVR2) gene during human gastrointestinal carcinogenesis. Two 8-bp polyadenine tracts of the ACVR2 gene are targets for inactivating frameshift mutations in gastrointestinal neoplasms having microsatellite instability (MSI). These mutations are similar to those of the 10-bp polyadenine tract within the TGF-ß type II receptor (TGFBR2), a well-characterized target of frameshift mutations in the same neoplasms. We identified biallelic mutations of ACVR2 in 25 of 28 MSI colorectal and pancreatic cancers. In addition, a mutation in the ACVR2 gene combined with loss of the wild-type allele was found in a non-MSI pancreatic cancer. This evidence is compatible with a high degree of selection for inactivation of the ACVR2 gene in tumorigenesis, supporting ACVR2 as a candidate tumor suppressor gene in gastrointestinal cancers.




This article has been cited by other articles:


Home page
 GlycobiologyHome page
G. Patsos, S. Andre, N. Roeckel, R. Gromes, J. Gebert, J. Kopitz, and H.-J. Gabius
Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): A gene-dependent effect on the cell surface glycan profile
Glycobiology, July 1, 2009; 19(7): 726 - 734.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Roeckel, S. M. Woerner, M. Kloor, Y.-P. Yuan, G. Patsos, R. Gromes, J. Kopitz, and J. Gebert
High Frequency of LMAN1 Abnormalities in Colorectal Tumors with Microsatellite Instability
Cancer Res., January 1, 2009; 69(1): 292 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. A. Pangas, C. J. Jorgez, M. Tran, J. Agno, X. Li, C. W. Brown, T. R. Kumar, and M. M. Matzuk
Intraovarian Activins Are Required for Female Fertility
Mol. Endocrinol., October 1, 2007; 21(10): 2458 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A Gylling, W M Abdel-Rahman, M Juhola, K Nuorva, E Hautala, H J Jarvinen, J-P Mecklin, M Aarnio, and P Peltomaki
Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study
Gut, July 1, 2007; 56(7): 926 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. E. Beck, B. H. Jung, A. Fiorino, J. Gomez, E. D. Rosario, B. L. Cabrera, S. C. Huang, J. Y. C. Chow, and J. M. Carethers
Bone morphogenetic protein signaling and growth suppression in colon cancer.
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G135 - G145.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno and M. Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
N. T. Takaesu, E. Herbig, D. Zhitomersky, M. B. O'Connor, and S. J. Newfeld
DNA-binding domain mutations in SMAD genes yield dominant-negative proteins or a neomorphic protein that can activate WG target genes in Drosophila
Development, November 1, 2005; 132(21): 4883 - 4894.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Deacu, Y. Mori, F. Sato, J. Yin, A. Olaru, A. Sterian, Y. Xu, S. Wang, K. Schulmann, A. Berki, et al.
Activin Type II Receptor Restoration in ACVR2-Deficient Colon Cancer Cells Induces Transforming Growth Factor-{beta} Response Pathway Genes
Cancer Res., November 1, 2004; 64(21): 7690 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y.-Q. Zhang, M. M. Cleary, Y. Si, G. Liu, Y. Eto, M. Kritzik, S. Dabernat, A. G. Kayali, and N. Sarvetnick
Inhibition of Activin Signaling Induces Pancreatic Epithelial Cell Expansion and Diminishes Terminal Differentiation of Pancreatic {beta}-Cells
Diabetes, August 1, 2004; 53(8): 2024 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Y. Zhou, S. Scolavino, S. F. Funderburk, L. F. Ficociello, X. Zhang, and A. Klibanski
Receptor Internalization-Independent Activation of Smad2 in Activin Signaling
Mol. Endocrinol., July 1, 2004; 18(7): 1818 - 1826.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. S. Calhoun, J. B. Jones, R. Ashfaq, V. Adsay, S. J. Baker, V. Valentine, P. M. Hempen, W. Hilgers, C. J. Yeo, R. H. Hruban, et al.
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer: Potential Therapeutic Targets
Am. J. Pathol., October 1, 2003; 163(4): 1255 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. S. Li, N.-G. Kim, S. H. Kim, C. Park, H. Kim, H. J. Kang, K. H. Koh, S. N. Kim, W. H. Kim, N. K. Kim, et al.
Chromosomal Imbalances in the Colorectal Carcinomas with Microsatellite Instability
Am. J. Pathol., October 1, 2003; 163(4): 1429 - 1436.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.